Teva Pharmaceutical Industries Limited
TEVA · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.26 | 0.54 | -0.10 | 0.56 |
| FCF Yield | 1.01% | 0.68% | -1.33% | 3.15% |
| EV / EBITDA | 34.41 | 52.64 | 42.90 | 34.21 |
| Quality | ||||
| ROIC | 2.08% | 2.19% | 1.40% | -0.11% |
| Gross Margin | 51.43% | 50.34% | 48.24% | 50.13% |
| Cash Conversion Ratio | 0.85 | 0.80 | -0.49 | -4.18 |
| Growth | ||||
| Revenue 3-Year CAGR | 3.18% | 3.45% | 3.64% | 3.49% |
| Free Cash Flow Growth | 77.86% | 156.47% | -129.52% | 44.22% |
| Safety | ||||
| Net Debt / EBITDA | 13.46 | 23.38 | 19.98 | 12.72 |
| Interest Coverage | 4.22 | 1.57 | 2.31 | 0.04 |
| Efficiency | ||||
| Inventory Turnover | 0.65 | 0.59 | 0.62 | 0.70 |
| Cash Conversion Cycle | 116.58 | 120.16 | 121.04 | 99.41 |